Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...
The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a key CDC panel ...
As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than ...
The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement ...
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making ...
The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results